Cargando…

Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study

BACKGROUND: The CC-chemokine receptor 4 (CCR4) is thought potentially to play a critical role in asthma pathogenesis due to its ability to recruit type 2 T-helper lymphocytes to the inflamed airways. Therefore, CCR4 provides an excellent target for anti-inflammatory therapy. METHODS: The safety, tol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cahn, Anthony, Hodgson, Simon, Wilson, Robert, Robertson, Jonathan, Watson, Joanna, Beerahee, Misba, Hughes, Steve C, Young, Graeme, Graves, Rebecca, Hall, David, van Marle, Sjoerd, Solari, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599276/ https://www.ncbi.nlm.nih.gov/pubmed/23448278 http://dx.doi.org/10.1186/2050-6511-14-14

Ejemplares similares

Structure of CC Chemokine Receptor 2 with Orthosteric and Allosteric Antagonists
por: Zheng, Yi, et al.
Publicado: (2016)

The CEBPE rs2239633 genetic polymorphism on susceptibility to childhood acute lymphoblastic leukemia: an updated meta-analysis
por: Liu, Jin, et al.
Publicado: (2021)

The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective mu-opioid receptor antagonist GSK1521498 in healthy subjects
por: Ziauddeen, Hisham, et al.
Publicado: (2013)

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects
por: Miller, Bruce E., et al.
Publicado: (2015)

Bayesian approach to investigate a two-state mixed model of COPD exacerbations
por: Largajolli, Anna, et al.
Publicado: (2019)

Correction to: Bayesian approach to investigate a two-state mixed model of COPD exacerbations
por: Largajolli, Anna, et al.
Publicado: (2019)

Development of a human antibody that exhibits antagonistic activity toward CC chemokine receptor 7
por: Jang, Moon-Sung, et al.
Publicado: (2022)

Hypoxia Alters the Expression of CC Chemokines and CC Chemokine Receptors in a Tumor–A Literature Review
por: Korbecki, Jan, et al.
Publicado: (2020)

A Novel Method for Analysing Frequent Observations from Questionnaires in Order to Model Patient-Reported Outcomes: Application to EXACT® Daily Diary Data from COPD Patients
por: Germovsek, Eva, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies
por: Laille, Eric, et al.
Publicado: (2015)

A Highly Selective Cc Chemokine Receptor (Ccr)8 Antagonist Encoded by the Poxvirus Molluscum Contagiosum
por: Lüttichau, Hans R., et al.
Publicado: (2000)

Synthesis and Pharmacological Evaluation of Triazolopyrimidinone Derivatives as Noncompetitive, Intracellular Antagonists for CC Chemokine Receptors 2 and 5
por: Ortiz Zacarías, Natalia V., et al.
Publicado: (2019)

The Role of CC-Chemokines in the Regulation of Angiogenesis
por: Ridiandries, Anisyah, et al.
Publicado: (2016)

The roles of CC chemokines in response to radiation
por: Wang, Lei, et al.
Publicado: (2022)

Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonists
por: Ajram, Laura, et al.
Publicado: (2014)

Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study
por: Church, Alison, et al.
Publicado: (2014)

Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours
por: Scotton, C, et al.
Publicado: (2001)

Structural basis of the activation of the CC chemokine receptor 5 by a chemokine agonist
por: Isaikina, Polina, et al.
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors
por: Santoni, Matteo, et al.
Publicado: (2014)

Selected CC and CXC chemokines in children with atopic asthma
por: Machura, Edyta, et al.
Publicado: (2016)

Role of CC-chemokine ligand 2 in gynecological cancer
por: Zhang, Jia-Jia, et al.
Publicado: (2022)

Structural basis of antibody inhibition and chemokine activation of the human CC chemokine receptor 8
por: Sun, Dawei, et al.
Publicado: (2023)

Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD
por: Mehta, Rashmi, et al.
Publicado: (2018)

Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist
por: Wyant, Timothy, et al.
Publicado: (2008)

Population Pharmacokinetics and Pharmacodynamics of GSK961081 (Batefenterol), a Muscarinic Antagonist and β(2)-Agonist, in Moderate-to-Severe COPD Patients: Substudy of a Randomized Trial
por: Ambery, Claire L., et al.
Publicado: (2015)

The role of CC-chemokine receptor 4 in murine polymicrobial sepsis
por: Maier, Stefan, et al.
Publicado: (2007)

Study of CC chemokine receptor 5 in renal allograft rejection
por: Ghosh, R., et al.
Publicado: (2013)

CC Chemokine Receptor 5: The Interface of Host Immunity and Cancer
por: de Oliveira, Carlos Eduardo Coral, et al.
Publicado: (2014)

CC chemokines and receptors in osteoarthritis: new insights and potential targets
por: Zhang, Yuchen, et al.
Publicado: (2023)

An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension
por: Simon, Marc A., et al.
Publicado: (2022)

Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients
por: Llanos-Paez, Carolina, et al.
Publicado: (2022)

Joint longitudinal model-based meta-analysis of FEV(1) and exacerbation rate in randomized COPD trials
por: Llanos-Paez, Carolina, et al.
Publicado: (2023)

Chemokine-like factor 1 is a functional ligand for CC chemokine receptor 4 (CCR4)
por: Wang, Ying, et al.
Publicado: (2006)

Natural Proteolytic Processing of Hemofiltrate Cc Chemokine 1 Generates a Potent Cc Chemokine Receptor (Ccr)1 and Ccr5 Agonist with Anti-HIV Properties
por: Detheux, Michel, et al.
Publicado: (2000)

CC chemokine receptor 7 promotes macrophage recruitment and induces M2-polarization through CC chemokine ligand 19&21 in oral squamous cell carcinoma
por: Zhou, Wan-Hang, et al.
Publicado: (2022)

Cc Chemokine Receptor 2 Is Critical for Induction of Experimental Autoimmune Encephalomyelitis
por: Fife, Brian T., et al.
Publicado: (2000)

The CC chemokine RANTES as a potential contributor to breast cancer progression
por: Azenshtein, E, et al.
Publicado: (2001)

Involvement of CC-chemokine receptor 2 in sepsis: focus on cognitive impairment
por: da Cunha, Mariana Gisely Amarante Teixeira, et al.
Publicado: (2013)

CC Chemokine Ligand 18 Correlates with Malignant Progression of Prostate Cancer
por: Chen, Guo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9rd7g9j54ie4nr55eg6cq47cnf